AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9207754 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination plus MDT
Number of subjects: 125
Study 9207754 — intervention group
Group type: COMPARATOR
Intervention: Killed Mycobacterium leprae vaccine plus MDT
Number of subjects: 125
Study 9207754 — intervention group
Group type: COMPARATOR
Intervention: MDT alone
Number of subjects: 125
Study 1539776 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 40 mg 12 hourly alone
Number of subjects: 162
Study 1539776 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 40 mg 12 hourly with sodium citrate
Number of subjects: 162
Study 1539776 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg 6 hourly with sodium citrate
Number of subjects: 162
Study 1539776 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium citrate
Number of subjects: 162
Study 3932052 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms
Number of subjects: 421
Study 3932052 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 421
Study 3932052 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 300 mg
Number of subjects: 421
Study 3932052 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smokers in misoprostol groups
Number of subjects: 421
Study 3932052 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers in misoprostol groups
Number of subjects: 421
Study 3932052 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 421
Study 31718597 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-month multi-component intervention including school lunchbox nutrition guidelines, curriculum lessons, information pushed to parents via a school-based communication application, and additional parent resources.
Number of subjects: 36
Study 31718597 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard school practices)
Number of subjects: 36
Study 29339351 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher target blood pressure (70-80 mmHg) during cardiopulmonary bypass
Number of subjects: 197
Study 29339351 — intervention group
Group type: COMPARATOR
Intervention: Lower target blood pressure (40-50 mmHg) during cardiopulmonary bypass
Number of subjects: 197
Study 26894485 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg daily for 7 days
Number of subjects: 213
Study 26894485 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 213
Study 24315135 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 30
Study 24315135 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30
Study 21887538 — intervention group
Group type: EXPERIMENTAL
Intervention: Press-fit fixation with a porous bone cylinder (P)
Number of subjects: 20
Study 21887538 — intervention group
Group type: COMPARATOR
Intervention: Interference screw fixation (I)
Number of subjects: 20
Study 21887538 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (P and I)
Number of subjects: 20
Study 21887538 — intervention group
Group type: EXPERIMENTAL
Intervention: Press-fit fixation (P)
Number of subjects: 20
Study 19933688 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 1100
Study 19933688 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 1100
Study 18091289 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-only motivational interviewing (MI) intervention with a pedometer and monthly MI telephone calls over 6 months
Number of subjects: 86
Study 18091289 — intervention group
Group type: COMPARATOR
Intervention: Control group with equal number of telephone calls without MI content
Number of subjects: 86
Study 15939582 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (600 mg) four times a day for 5 days
Number of subjects: 23
Study 15939582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12835432 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-coated brackets
Number of subjects: 33
Study 12835432 — intervention group
Group type: COMPARATOR
Intervention: Non-pre-coated brackets
Number of subjects: 33
Study 11074181 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg per day
Number of subjects: 29
Study 11074181 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 2000 mg per day
Number of subjects: 29
Study 11074181 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 3000 mg per day
Number of subjects: 29
Study 11074181 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 4000 mg per day
Number of subjects: 29
Study 11074181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11074181 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (any dose)
Number of subjects: 29
Study 9004249 — intervention group
Group type: EXPERIMENTAL
Intervention: NG‐nitro‐L‐arginine methyl ester (L‐NAME) 40 micrograms/kg injected plus 50 micrograms/kg infused over 60 min
Number of subjects: 0
Study 9004249 — intervention group
Group type: EXPERIMENTAL
Intervention: NG‐nitro‐L‐arginine methyl ester (L‐NAME)
Number of subjects: 0
Study 1627424 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cyclophosphamide, methotrexate, fluorouracil, and prednisone for six cycles)
Number of subjects: 788
Study 1627424 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 788
Study 7458118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalozoline administered 1 hour before and 5 and 12 hours after surgery
Number of subjects: 665
Study 7458118 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol administered 1 hour before and 5 and 12 hours after surgery
Number of subjects: 665
Study 7458118 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cephalozoline and thiamphenicol administered 1 hour before and 5 and 12 hours after surgery
Number of subjects: 665
Study 7458118 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics administered (control group)
Number of subjects: 665
Study 31789656 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-scale computational fluid dynamics (CFD) model applied to small oxygenator prototypes
Number of subjects: 0
Study 31789656 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory oxygenator prototypes tested in vitro with porcine blood
Number of subjects: 0
Study 28674147 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold Coast Integrated Care (GCIC)
Number of subjects: 1500
Study 28674147 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 1500
Study 25972155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal butorphanol
Number of subjects: 260
Study 25972155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous butorphanol
Number of subjects: 260
Study 25972155 — intervention group
Group type: COMPARATOR
Intervention: Intranasal fentanyl
Number of subjects: 260
Study 25972155 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (control)
Number of subjects: 260
Study 24021297 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-based dosing of Genotropin® GH (0.18 to 0.7 mg/kg/week)
Number of subjects: 316
Study 24021297 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of Genotropin® (0.37 mg/kg/week)
Number of subjects: 316
Study 20844485 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg) with clopidogrel (300 mg loading dose/75 mg/day maintenance dose)
Number of subjects: 282
Study 20844485 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose/75 mg/day maintenance dose) administered 12 hours apart from omeprazole (80 mg)
Number of subjects: 282
Study 20844485 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg loading dose/150 mg/day maintenance dose) with omeprazole (80 mg)
Number of subjects: 282
Study 20844485 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (80 mg) with clopidogrel (300 mg loading dose/75 mg/day maintenance dose)
Number of subjects: 282
Study 19282345 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants (n = 889)
Number of subjects: 2500
Study 19282345 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipants (n = 97)
Number of subjects: 2500
Study 17845652 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral interscalene technique (Winnie)
Number of subjects: 40
Study 17845652 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior interscalene technique (Pippa)
Number of subjects: 40
Study 17845652 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary technique
Number of subjects: 40
Study 17845652 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical infraclavicular technique
Number of subjects: 40
Study 16918592 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet) 0.3 U/kg
Number of subjects: 48
Study 16918592 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet) 0.6 U/kg
Number of subjects: 48
Study 16918592 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet) 1.2 U/kg
Number of subjects: 48
Study 16918592 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin 0.3 IU/kg
Number of subjects: 48
Study 16918592 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin 0.6 IU/kg
Number of subjects: 48
Study 16918592 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin 1.2 IU/kg
Number of subjects: 48
Study 14560411 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross-linked, ultrahigh-molecular-weight polyethylenes (UHMWPEs) used in arthroplasty.
Number of subjects: 0
Study 14560411 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro examination of UHMWPEs.
Number of subjects: 0
Study 10725985 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynera
Number of subjects: 67
Study 10725985 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgynon 30
Number of subjects: 67
Study 7481865 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive surgical staging
Number of subjects: 0
Study 7481865 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 0
Study 7481865 — intervention group
Group type: COMPARATOR
Intervention: Various adjuvant treatments
Number of subjects: 0
Study 1688988 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CLS 2210)
Number of subjects: 41
Study 6992186 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading a confusion color chart based on the principle of interference in color perception
Number of subjects: 5
Study 6992186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressure test
Number of subjects: 5
Study 6992186 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric stress with a hand ergometer
Number of subjects: 5
Study 6992186 — intervention group
Group type: COMPARATOR
Intervention: Adaptation phase
Number of subjects: 5
Study 28543407 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood stabilizer treatment
Number of subjects: 0
Study 28543407 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 27507930 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 17
Study 27507930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 27507930 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (all participants)
Number of subjects: 17
Study 25429898 — intervention group
Group type: EXPERIMENTAL
Intervention: OSNAP‐OPAT
Number of subjects: 528
Study 23751742 — intervention group
Group type: EXPERIMENTAL
Intervention: GRP78 positive cells in ovarian serous adenocarcinoma
Number of subjects: 126
Study 23751742 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA expressions of GRP78
Number of subjects: 126
Study 23751742 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein expressions of GRP78
Number of subjects: 126
Study 23751742 — intervention group
Group type: EXPERIMENTAL
Intervention: GRP78 expression
Number of subjects: 126
Study 23751742 — intervention group
Group type: EXPERIMENTAL
Intervention: GRP78 mRNA and protein expression
Number of subjects: 126
Study 20834185 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Erythropoietin (6,000 IU during PCI, 24h and 48h)
Number of subjects: 35
Study 20834185 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 35
Study 19098656 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidified CO2
Number of subjects: 565
Study 19098656 — intervention group
Group type: COMPARATOR
Intervention: Standard dry CO2
Number of subjects: 565
Study 15803314 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg/day; n = 20)
Number of subjects: 40
Study 15803314 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5 mg/day; n = 20)
Number of subjects: 40
Study 12464839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain education program
Number of subjects: 37
Study 10329810 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 25 micrograms to 500 micrograms, twice daily
Number of subjects: 1461
Study 10329810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1461
Study 7851579 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17 beta-E2 with high dose of CPA
Number of subjects: 65
Study 7851579 — intervention group
Group type: COMPARATOR
Intervention: Transdermal 17 beta-E2 with high dose of CPA
Number of subjects: 65
Study 2046254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacizine
Number of subjects: 77
Study 2046254 — intervention group
Group type: COMPARATOR
Intervention: Bonnecor
Number of subjects: 77
Study 7015912 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (topical corticosteroid)
Number of subjects: 22
Study 7015912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31848231 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate disease-modifying therapy (DMT)
Number of subjects: 328
Study 31848231 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed disease-modifying therapy (DMT)
Number of subjects: 328
Study 31113794 — intervention group
Group type: EXPERIMENTAL
Intervention: ixekizumab
Number of subjects: 402
Study 31113794 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 402
Study 28640124 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia machine: Excel, Avance, Cato, Primus with low-flow anesthesia (0.5, 1, and 4 L/min)
Number of subjects: 99
Study 28640124 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia machine: Cato and Primus with fresh gas flow of 4 L/min
Number of subjects: 99
Study 28640124 — intervention group
Group type: EXPERIMENTAL
Intervention: All anesthesia machines with low-flow anesthesia
Number of subjects: 99
Study 25888851 — intervention group
Group type: EXPERIMENTAL
Intervention: SrRan 2 g/day
Number of subjects: 330
Study 25888851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 24007540 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth Preparation Program (BPP)
Number of subjects: 21
Study 24007540 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care (Control)
Number of subjects: 21
Study 21309961 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5 mg/24 h rivastigmine patch
Number of subjects: 0
Study 21309961 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.3 mg/24 h rivastigmine patch
Number of subjects: 0
Study 21309961 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/day rivastigmine capsules
Number of subjects: 0
Study 21309961 — intervention group
Group type: COMPARATOR
Intervention: 4.6 mg/24 h rivastigmine patch
Number of subjects: 0
Study 21309961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18704426 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTNFR:Fc (25 mg, subcutaneous injection, twice weekly)
Number of subjects: 238
Study 16996230 — intervention group
Group type: EXPERIMENTAL
Intervention: ST brand switching with controlled ST topography
Number of subjects: 0
Study 16996230 — intervention group
Group type: EXPERIMENTAL
Intervention: ST brand switching with ad libitum ST use
Number of subjects: 0
Study 16996230 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 15528877 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte and monocyte adsorption apheresis
Number of subjects: 20
Study 15528877 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 20
Study 11057435 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg
Number of subjects: 411
Study 11057435 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 411
Study 11057435 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 411
Study 9309627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-training (C)
Number of subjects: 16
Study 9309627 — intervention group
Group type: COMPARATOR
Intervention: Endurance-only (E)
Number of subjects: 16
Study 8340716 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized force of 2 or 3 kg applied with a 1 cm2 rubber-tipped pressure algometer
Number of subjects: 42
Study 8340716 — intervention group
Group type: COMPARATOR
Intervention: Sham test
Number of subjects: 42
Study 3529677 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (daily dose 400 I.E. d‐alpha‐tocopherylacetate)
Number of subjects: 50
Study 3529677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3529677 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 50
Study 3529677 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E and Placebo
Number of subjects: 50
Study 31026298 — intervention group
Group type: EXPERIMENTAL
Intervention: Social and preventive medicine consultation (intervention group)
Number of subjects: 976
Study 31026298 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 976
Study 28760534 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized Japanese cedar pollen extract
Number of subjects: 482
Study 28760534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 482
Study 26991399 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg twice daily (b.d.)
Number of subjects: 28
Study 26991399 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg daily
Number of subjects: 28
Study 26991399 — intervention group
Group type: COMPARATOR
Intervention: esomeprazole 20 mg b.d.
Number of subjects: 28
Study 26991399 — intervention group
Group type: COMPARATOR
Intervention: esomeprazole 20 mg daily
Number of subjects: 28
Study 25419402 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded deep inhale training
Number of subjects: 30
Study 25419402 — intervention group
Group type: COMPARATOR
Intervention: Regular aerobics (jogging)
Number of subjects: 30
Study 22796949 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to palatable food
Number of subjects: 0
Study 20096622 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal spray
Number of subjects: 22
Study 20096622 — intervention group
Group type: COMPARATOR
Intervention: Saline spray (control)
Number of subjects: 22
Study 18671464 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment options including surgery, radiotherapy, and systemic chemotherapy.
Number of subjects: 0
Study 15972867 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 24-week regimen of peginterferon alfa-2b at a dose of 1.0 mug per kilogram weekly plus ribavirin at a dose of 1000 mg or 1200 mg daily.
Number of subjects: 283
Study 15972867 — intervention group
Group type: COMPARATOR
Intervention: Variable 12 or 24-week regimen depending on HCV RNA results at week 4.
Number of subjects: 283
Study 15972867 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 24-week regimen
Number of subjects: 283
Study 15972867 — intervention group
Group type: COMPARATOR
Intervention: Variable 12 or 24-week regimen
Number of subjects: 283
Study 15972867 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable 12-week regimen
Number of subjects: 283
Study 15972867 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response for genotype 2
Number of subjects: 283
Study 15972867 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response for genotype 3
Number of subjects: 283
Study 12571845 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 40 mg
Number of subjects: 68
Study 12571845 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 68
Study 10929792 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD group
Number of subjects: 117
Study 10929792 — intervention group
Group type: EXPERIMENTAL
Intervention: PD group
Number of subjects: 117
Study 10929792 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 117
Study 8765493 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP) treatment, 30 mg/kg orally for 4 days
Number of subjects: 14
Study 8765493 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP) treatment
Number of subjects: 14
Study 8765493 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HDMP treatment)
Number of subjects: 14
Study 1532974 — intervention group
Group type: EXPERIMENTAL
Intervention: Single drug therapy for induction of remission
Number of subjects: 1563
Study 1532974 — intervention group
Group type: COMPARATOR
Intervention: Single drug therapy for maintenance of remission
Number of subjects: 1563
Study 3894396 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate
Number of subjects: 22
Study 3894396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31975536 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio (WHR) increase by 10%
Number of subjects: 0
Study 27664111 — intervention group
Group type: EXPERIMENTAL
Intervention: GLUC-NAS
Number of subjects: 10
Study 27664111 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-NAS
Number of subjects: 10
Study 27664111 — intervention group
Group type: COMPARATOR
Intervention: PLAC-NAS
Number of subjects: 10
Study 25670541 — intervention group
Group type: EXPERIMENTAL
Intervention: C-HART (30 Gy/2 Gy daily followed by twice-daily 1.4 Gy to a total of 70.6 Gy with concurrent mitomycin C/5-FU)
Number of subjects: 384